BillionToOne, Inc. (BLLN) stock
Close on Nov 12, 2026Market cap $5.23BP/E –Yield –
BillionToOne, Inc. grew revenue 71.9% to $436.87M over the twelve months to Sep 30, 2026. Free cash flow was $33.90M. At the latest close the market valued the company at $5.23B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $5.23B
- P/E ratio
- –
- Price to sales
- 11.97
- Price to book
- 9.23
- Dividend yield
- –
- Free cash flow yield
- 0.65%
Fundamentals
- Revenue
- $436.87M
- Net income
- $49.39M
- EPS, diluted
- $0.14
- Free cash flow
- $33.90M
- Book value per share
- $10.54
- Diluted shares
- 54M
Trading
- Next earnings
- Mar 3, 2027 (estimated, after the close)
- Previous close
- $110.23
- Open
- $107.25
- Day's range
- $106.46 – $111.07
- Volume
- 582,289
- Average volume (20 days)
- 616,557
- 52-week range
- $61.96 – $150.44
- RSI (14 days)
- 52.6
- Volatility (1 year)
- 87.0%
- Relative volume
- 0.88×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BLLN | S&P 500 | Difference | BLLN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +19.0% | -2.7% | +21.7 pts | ||
| 3 months | +13.7% | -1.7% | +15.4 pts | ||
| Year to date | +35.4% | +11.9% | +23.5 pts | ||
| 1 year | +8.8% | +12.0% | −3.2 pts | ||
| 3 years | +1107800.0% | +78.2% | +1107721.8 pts | +2129.3% | +21.2% |
| 5 years | +1107800.0% | +73.2% | +1107726.8 pts | +544.0% | +11.6% |
| 10 years | +1107800.0% | +309.6% | +1107490.4 pts | +153.8% | +15.1% |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BillionToOne filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About BillionToOne
Services-Medical Laboratories
BillionToOne, Inc. operates as a precision molecular diagnostics company specializing in non-invasive single-molecule next-generation sequencing tests. The organization develops liquid biopsy screening tools utilizing cell-free DNA to assess fetal genetic conditions and evaluate oncology therapy outcomes. Its prenatal portfolio includes the UNITY suite of maternal blood tests, which screen for recessive genetic conditions, chromosomal aneuploidies, microdeletions, and fetal red blood cell antigens. In oncology, the firm offers Northstar Select for solid tumor therapy guidance and Northstar Response for monitoring treatment efficacy and quantifying tumor burden. The company's primary customers include obstetricians, maternal-fetal medicine specialists, oncologists, healthcare systems, and clinical trial partners.
Company profile, executives and historyBillionToOne stock: common questions
What is BillionToOne's stock price?
BLLN closed at $110.79 on Nov 12, 2026, up 0.51% on the day. Over the past 52 weeks it traded between $61.96 and $150.44.
What is BillionToOne's market cap?
BillionToOne was worth $5.23B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
How much revenue does BillionToOne make?
BillionToOne reported revenue of $436.87M for the twelve months to Sep 30, 2026, up 71.9% from a year earlier.
Does BillionToOne pay a dividend?
No. BillionToOne has not paid a cash dividend over the last twelve months.
When does BillionToOne report earnings next?
BillionToOne is expected to report Q4 FY2026 results on Mar 3, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BLLN stock performed over the past year?
Including dividends, BLLN returned +8.8% over the past year, against +12.0% for the S&P 500.
How many BLLN shares are sold short?
3M shares were sold short at the latest FINRA report, 14.21% of the float, or 6.7 days of average trading volume.
Who are BillionToOne's competitors?
Companies most similar to BillionToOne by business, industry and size include CSTL, VCYT, BNR, CDNA, GRAL.
See a number that looks wrong?